Read the full article below.
News
21/03/2025
EnteroBiotix Announces Positive Topline Phase 2a Results with EBX-102-02, a Potential First-in-Class Treatment for Irritable Bowel Syndrome (IBS)
Our news
News
25/09/2024
European Microbiome Innovation for Health and Microbiome Therapeutics Innovation Group join forces with Microbiome Times on important deal-making event, taking place Brussels 2025
> READ
European Microbiome Innovation for Health and Microbiome Therapeutics Innovation Group join forces with Microbiome Times on important deal-making event, taking place Brussels 2025
> READ
News
02/06/2025
MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease
> READ
MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease
> READ
News
09/05/2025
Microbiotica unveils multiple mechanisms by which MB310, in clinical development for the treatment of ulcerative colitis, protects the intestinal barrier
> READ
Microbiotica unveils multiple mechanisms by which MB310, in clinical development for the treatment of ulcerative colitis, protects the intestinal barrier
> READ
> See all news